Sandoz wins UK bid to invalidate Biogen’s brain infection risk-assessment method patent
By Abhishek Kumar ( October 11, 2024, 19:05 GMT | Insight) -- US drugmaker Biogen’s patented method for assessing the risk that multiple sclerosis patients will develop progressive multifocal leukoencephalopathy was declared invalid by the UK High Court. Biogen claimed Sandoz challenged the patented method to clear the way for the launch of a planned biosimilar to Tysabri, Biogen’s flagship MS drug.A European patent owned by US drugmaker Biogen which assesses the risk of developing progressive multifocal leukoencephalopathy, or PML, was declared “plainly invalid” by the UK High Court today....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.